-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120

Benzinga·07/23/2026 18:00:11
Listen to the news
Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $100 to $120.